A scientific reference in its sector of activity.
Vésale Pharma, a pioneer in its field, specializes in the clinical and galenical research and development of based probiotics treatments.
From the beginning, Vésale Pharma has set up a vast R&D plan in its various therapeutic areas.
These research programs pursue a major objective: to develop new safe and effective health products and innovative pharmaceutical products for major health and well-being needs that have not yet been satisfactorily addressed.
Vésale Pharma works in partnership with university research teams from the University of Liège and Ghent (Belgium) and from the Texas A&M University (USA) or with the Institut Pasteur in Lille, as well as Belgian and international laboratories and medical practitioners.
All strains of Vésale Pharma are documented; they have been and still are the subject of R&D.
The company holds several worldwide patents (notably the revolutionary Intelicaps® patent), Vésale Pharma currently structures its Research & Development activity around several major axes: Immunity, Intelicaps technology and anti-infective treatments.
Five years after Intelicaps, a research opens up a new avenue in the development of new anti-infective treatments other than antibiotics : the development of sonication technology applied to probiotics has enabled Vésale Pharma to make a major advance in the area of anti-infective treatments , in particular in the case of urogenital infections.
A worldwide patent application has just been submitted for this discovery.
Among the major ongoing research, Vésale Pharma has discovered remarkable anti-inflammatory properties on limitation of weight gain and cardiovascular disease, of one of its strains, VES002. It has been confirmed in studies carried out in collaboration with the Pasteur Institute of Lille that the administration of the strain VES002 not only had a beneficial impact never observed on the limitation of weight gain but also induced significant improvements of Associated immune and metabolic parameters or, in other words, of factors predisposing to type 2 diabetes and cardiovascular diseases.
The results of this study were published in the scientific journal of reference Environmental Microbiology published by the Society for Applied Microbiology and presented at the PreProPed 2016 International Scientific Congress held in Ghent.
These results are being studied further and are followed by extensive clinical studies since 2017.
Intelicaps® technology is a unique process in the world of microencapsulation of probiotic strains which offers them unmatched protection and delivery.
The Walloon company signed a memorandum of understanding on December 7 with Texas A&M University based at College Station, not far from Houston. Studies with Texas A&M University focus on the influence of Intelicaps® technology on various parameters such as colonization, inflammatory reduction and immuno-modulation.
Other Research Projects
Other research and studies are in the initial phase of launch and focus on the potentialities of the Vésale strains in different therapeutic areas such as immunology, gynecology, gastroenterology, …